Deschloroketamine (DXE, DCK, 2'-Oxo-PCM) is a dissociative anesthetic that has been sold online as a designer drug. It has also been proposed for the treatment of bacterial, fungal, viral or protozoal infections and for immunomodulation at doses of 2 mg per day.
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||203.285 g·mol−1|
|3D model (JSmol)|
In 2019, it becomes part of a group of molecules studied by the french laboratory Caulredaitens.
Deschloroketamine is illegal in Latvia, and is covered by blanket bans in Canada and the UK.
- Robins EG, Zhao Y, Khan I, Wilson A, Luthra SK, Rstad E (March 2010). "Synthesis and in vitro evaluation of (18)F-labelled S-fluoroalkyl diarylguanidines: Novel high-affinity NMDA receptor antagonists for imaging with PET". Bioorganic & Medicinal Chemistry Letters. 20 (5): 1749–51. doi:10.1016/j.bmcl.2010.01.052. PMID 20138515.
- US 3254124, Stevens CL, "Aminoketones and methods for their production", published 31 May 1966
- Frison G, Zamengo L, Zancanaro F, Tisato F, Traldi P (January 2016). "Characterization of the designer drug deschloroketamine (2-methylamino-2-phenylcyclohexanone) by gas chromatography/mass spectrometry, liquid chromatography/high-resolution mass spectrometry, multistage mass spectrometry, and nuclear magnetic resonance". Rapid Communications in Mass Spectrometry. 30 (1): 151–60. doi:10.1002/rcm.7425. PMID 26661982.
- "Alerta: descloroketamina vendida como ketamina en Barcelona" (in Spanish). Energy Control. Retrieved 2 October 2015.
- Villalba J (27 March 2015). "Los efectos desconocidos de la sequía de ketamina" (in Spanish). Vice. Retrieved 2 October 2015.
- Knibbs J (22 October 2015). "Party-drug testing shows its worth". The Medical Republic.
- Hájková K, Jurásek B, Čejka J, Štefková K, Páleníček T, Sýkora D, Kuchař M (October 2019). "Synthesis and identification of deschloroketamine metabolites in rats' urine and a quantification method for deschloroketamine and metabolites in rats' serum and brain tissue using liquid chromatography tandem mass spectrometry". Drug Testing and Analysis. doi:10.1002/dta.2726. PMID 31670910.
- DE 4409671, Preiss D, Tatar A, "Use of 2-methylamino-2-phenylcyclohexanone for the treatment of bacterial, fungal, viral or protozoal infections and for immunomodulation", published 23 May 1995
- "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" [Regulations on Narcotic Drugs, Psychotropic Substances and Precursors Controlled in Latvia] (in Latvian). Ministry of Health of the Republic of Latvia.